Sema4
Although the firm remains in the red, the new CEO is counting on testing volume growth, health system partnerships, and operational efficiencies including layoffs to reach profitability.
Sema4 Q1 Revenues Decline 16 Percent
The firm, which acquired GeneDx last month, recently cut its workforce by 10 percent as it charts a path to profitability.
In Brief This Week: Sema4, Mirvie, Caris Life Sciences, Prenetics, 23andMe, More
News items for the week of May 2, 2022.
In Brief This Week: Cardea Bio, Proof Diagnostics, Ginkgo Bioworks, Twist Bioscience, More
News items for the week of April 4, 2022.
Mar 15, 2022
Sema4 Q4 Revenues Decline 10 Percent
Jan 20, 2022
Jan 18, 2022
Sema4 to Acquire GeneDx for $623M
Dec 30, 2021
Top 10 Articles on GenomeWeb in 2021
Nov 15, 2021
Sema4 Q3 Revenues Rise 12 Percent
Oct 8, 2021
BTIG Initiates Coverage of Sema4 With Buy Rating
Aug 16, 2021
Sema4 Reports 56 Percent Increase in Q2 Revenues
Jul 22, 2021
Feb 26, 2021